403 related articles for article (PubMed ID: 20093438)
21. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia.
Ferrando AA; Neuberg DS; Staunton J; Loh ML; Huard C; Raimondi SC; Behm FG; Pui CH; Downing JR; Gilliland DG; Lander ES; Golub TR; Look AT
Cancer Cell; 2002 Feb; 1(1):75-87. PubMed ID: 12086890
[TBL] [Abstract][Full Text] [Related]
22. Identification of the LMO4 gene encoding an interaction partner of the LIM-binding protein LDB1/NLI1: a candidate for displacement by LMO proteins in T cell acute leukaemia.
Grutz G; Forster A; Rabbitts TH
Oncogene; 1998 Nov; 17(21):2799-803. PubMed ID: 9840944
[TBL] [Abstract][Full Text] [Related]
23. Identification of DeltaEF1 as a novel target that is negatively regulated by LMO2 in T-cell leukemia.
Sun W; Yang S; Shen W; Li H; Gao Y; Zhu TH
Eur J Haematol; 2010 Dec; 85(6):508-19. PubMed ID: 20731704
[TBL] [Abstract][Full Text] [Related]
24. The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development.
McCormack MP; Forster A; Drynan L; Pannell R; Rabbitts TH
Mol Cell Biol; 2003 Dec; 23(24):9003-13. PubMed ID: 14645513
[TBL] [Abstract][Full Text] [Related]
25. Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex.
El Omari K; Hoosdally SJ; Tuladhar K; Karia D; Vyas P; Patient R; Porcher C; Mancini EJ
Blood; 2011 Feb; 117(7):2146-56. PubMed ID: 21076045
[TBL] [Abstract][Full Text] [Related]
26. SCL, LMO1 and Notch1 reprogram thymocytes into self-renewing cells.
Gerby B; Tremblay CS; Tremblay M; Rojas-Sutterlin S; Herblot S; Hébert J; Sauvageau G; Lemieux S; Lécuyer E; Veiga DF; Hoang T
PLoS Genet; 2014 Dec; 10(12):e1004768. PubMed ID: 25522233
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of Lmo2 initiates T-lymphoblastic leukemia via impaired thymocyte competition.
Abdulla HD; Alserihi R; Flensburg C; Abeysekera W; Luo MX; Gray DHD; Liu X; Smyth GK; Alexander WS; Majewski IJ; McCormack MP
J Exp Med; 2023 Jun; 220(6):. PubMed ID: 36920307
[TBL] [Abstract][Full Text] [Related]
28. Epigenetic dysregulation of ZEB1 is involved in LMO2-promoted T-cell acute lymphoblastic leukaemia leukaemogenesis.
Wu C; Li J; Tian C; Shi W; Jiang H; Zhang Z; Wang H; Zhang Q; Sun W; Sun P; Xiang R; Yang S
Biochim Biophys Acta Mol Basis Dis; 2018 Aug; 1864(8):2511-2525. PubMed ID: 29778661
[TBL] [Abstract][Full Text] [Related]
29. The E2A-HLF oncogenic fusion protein acts through Lmo2 and Bcl-2 to immortalize hematopoietic progenitors.
de Boer J; Yeung J; Ellu J; Ramanujachar R; Bornhauser B; Solarska O; Hubank M; Williams O; Brady HJ
Leukemia; 2011 Feb; 25(2):321-30. PubMed ID: 21072044
[TBL] [Abstract][Full Text] [Related]
30. T-ALL can evolve to oncogene independence.
Abdulla H; Vo A; Shields BJ; Davies TJ; Jackson JT; Alserihi R; Viney EM; Wong T; Yan F; Wong NC; Demoen L; Curtis DJ; Alexander WS; Van Vlierberghe P; Dickins RA; McCormack MP
Leukemia; 2021 Aug; 35(8):2205-2219. PubMed ID: 33483615
[TBL] [Abstract][Full Text] [Related]
31. Expression of the leukemia oncogene Lmo2 is controlled by an array of tissue-specific elements dispersed over 100 kb and bound by Tal1/Lmo2, Ets, and Gata factors.
Landry JR; Bonadies N; Kinston S; Knezevic K; Wilson NK; Oram SH; Janes M; Piltz S; Hammett M; Carter J; Hamilton T; Donaldson IJ; Lacaud G; Frampton J; Follows G; Kouskoff V; Göttgens B
Blood; 2009 Jun; 113(23):5783-92. PubMed ID: 19171877
[TBL] [Abstract][Full Text] [Related]
32. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.
Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ
Leukemia; 2007 Apr; 21(4):754-63. PubMed ID: 17268520
[TBL] [Abstract][Full Text] [Related]
33. LMO2 expression is frequent in T-lymphoblastic leukemia and correlates with survival, regardless of T-cell stage.
Latchmansingh KA; Wang X; Verdun RE; Marques-Piubelli ML; Vega F; You MJ; Chapman J; Lossos IS
Mod Pathol; 2022 Sep; 35(9):1220-1226. PubMed ID: 35322192
[TBL] [Abstract][Full Text] [Related]
34. Fli1, Elf1, and Ets1 regulate the proximal promoter of the LMO2 gene in endothelial cells.
Landry JR; Kinston S; Knezevic K; Donaldson IJ; Green AR; Göttgens B
Blood; 2005 Oct; 106(8):2680-7. PubMed ID: 15994290
[TBL] [Abstract][Full Text] [Related]
35. The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia.
Van Vlierberghe P; van Grotel M; Beverloo HB; Lee C; Helgason T; Buijs-Gladdines J; Passier M; van Wering ER; Veerman AJ; Kamps WA; Meijerink JP; Pieters R
Blood; 2006 Nov; 108(10):3520-9. PubMed ID: 16873670
[TBL] [Abstract][Full Text] [Related]
36. LMO2 Is a Specific Marker of T-Lymphoblastic Leukemia/Lymphoma.
Jevremovic D; Roden AC; Ketterling RP; Kurtin PJ; McPhail ED
Am J Clin Pathol; 2016 Feb; 145(2):180-90. PubMed ID: 26796495
[TBL] [Abstract][Full Text] [Related]
37. Lmo2 expression defines tumor cell identity during T-cell leukemogenesis.
García-Ramírez I; Bhatia S; Rodríguez-Hernández G; González-Herrero I; Walter C; González de Tena-Dávila S; Parvin S; Haas O; Woessmann W; Stanulla M; Schrappe M; Dugas M; Natkunam Y; Orfao A; Domínguez V; Pintado B; Blanco O; Alonso-López D; De Las Rivas J; Martín-Lorenzo A; Jiménez R; García Criado FJ; García Cenador MB; Lossos IS; Vicente-Dueñas C; Borkhardt A; Hauer J; Sánchez-García I
EMBO J; 2018 Jul; 37(14):. PubMed ID: 29880602
[TBL] [Abstract][Full Text] [Related]
38. NKX3.1 is a direct TAL1 target gene that mediates proliferation of TAL1-expressing human T cell acute lymphoblastic leukemia.
Kusy S; Gerby B; Goardon N; Gault N; Ferri F; Gérard D; Armstrong F; Ballerini P; Cayuela JM; Baruchel A; Pflumio F; Roméo PH
J Exp Med; 2010 Sep; 207(10):2141-56. PubMed ID: 20855495
[TBL] [Abstract][Full Text] [Related]
39. Activation of the
Rahman S; Magnussen M; León TE; Farah N; Li Z; Abraham BJ; Alapi KZ; Mitchell RJ; Naughton T; Fielding AK; Pizzey A; Bustraan S; Allen C; Popa T; Pike-Overzet K; Garcia-Perez L; Gale RE; Linch DC; Staal FJT; Young RA; Look AT; Mansour MR
Blood; 2017 Jun; 129(24):3221-3226. PubMed ID: 28270453
[TBL] [Abstract][Full Text] [Related]
40. A comprehensive analysis of LMO2 pathogenic regulatory profile during T-lineage development and leukemic transformation.
Wang W; Meng Y; Chen Y; Yu Y; Wang H; Yang S; Sun W
Oncogene; 2022 Aug; 41(34):4079-4090. PubMed ID: 35851847
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]